HLB PANAGENE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,275 KRW | -2.84% |
|
-5.21% | +3.51% |
| Sales 2010 | 34.04B 24.75M 33.8M | Sales 2011 | 41.45B 30.14M 41.16M | Capitalization | 102B 74.33M 102M |
|---|---|---|---|---|---|
| Net income 2010 | -4.04B -2.94M -4.01M | Net income 2011 | -1.59B -1.16M -1.58M | EV / Sales 2010 | 5.62 x |
| Net Debt 2010 | 10.57B 7.69M 10.5M | Net Debt 2011 | 13.93B 10.13M 13.84M | EV / Sales 2011 | 2.8 x |
| P/E ratio 2010 |
-43.5
x | P/E ratio 2011 |
-64.2
x | Employees | 63 |
| Yield 2010 * |
-
| Yield 2011 |
-
| Free-Float | 63.57% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.84% | ||
| 1 week | -5.21% | ||
| Current month | -14.67% | ||
| 1 month | -16.99% | ||
| 3 months | -0.23% | ||
| 6 months | +25.00% | ||
| Current year | +3.51% |
1 week
4 130.00
4 725.00
1 month
4 130.005 310.00
Current year
3 590.005 450.00
1 year
3 005.006 720.00
3 years
2 675.006 720.00
5 years
1 100.006 720.00
10 years
1 100.0012 350.00
| Managers | Title | Age | Since |
|---|---|---|---|
In-Geun Jang
CEO | Chief Executive Officer | 48 | - |
Bong-Ho Eom
BRD | Director/Board Member | 51 | 03-07-31 |
Seung-Gyo Park
BRD | Director/Board Member | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Shik Park
PRN | Corporate Officer/Principal | 77 | 10-02-15 |
Jong-Boo Lim
BRD | Director/Board Member | 63 | 13-03-28 |
Yong-Hwan Lee
BRD | Director/Board Member | 63 | 17-03-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4,275 | -2.84% | 418,542 |
| 24-04-25 | 4,400 | -3.08% | 268,052 |
| 24-04-24 | 4,540 | +1.68% | 276,735 |
| 24-04-23 | 4,465 | -1.22% | 196,795 |
| 24-04-22 | 4,520 | +0.22% | 366,855 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
HLB PanaGene Co Ltd, formerly Panagene Inc, is a Korea-based company mainly engaged in the development of genetic diagnostic products. The Company operates its business through three segments. The Diagnostics Business segment mainly involves in manufacturing and sales of molecular diagnostic reagents, analysis services, and consumables. The Materials Business segment mainly engages in the manufacturing and sales of custom pentose nucleic acid (PNA) oligomers. The Nucleic Acid Extraction segment mainly engages in the manufacturing and sales of nucleic acid extraction equipment and extraction reagents.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.51% | 127M | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 377M |
- Stock Market
- Equities
- A046210 Stock
